[
    [
        {
            "time": "2018-03-15",
            "original_text": "Lilly: Phase 3 Soft Tissue Sarcoma Study Fails To Meet Primary Endpoints",
            "features": {
                "keywords": [
                    "Phase 3",
                    "Soft Tissue Sarcoma",
                    "Study Fails",
                    "Primary Endpoints"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly: Phase 3 Soft Tissue Sarcoma Study Fails To Meet Primary Endpoints",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-16",
            "original_text": "Eli Lilly’s Sarcoma Drug Combo Proves Ineffective in Trials",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Sarcoma",
                    "Drug Combo",
                    "Ineffective",
                    "Trials"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly’s Sarcoma Drug Combo Proves Ineffective in Trials",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-03-19",
            "original_text": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "LLY Stock",
                    "Falls",
                    "Sarcoma",
                    "Study Failure"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-04-25",
            "original_text": "Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients",
            "features": {
                "keywords": [
                    "Phase 3",
                    "REACH-2 Trial",
                    "CYRAMZA",
                    "Improvement",
                    "Overall Survival",
                    "Hepatocellular Carcinoma"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]